Skip to Main content Skip to Navigation
Journal articles

Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19

Abstract : Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to more than 150 million infections and about 3.1 million deaths up to date. Currently, drugs screened are urgently aiming to block the infection of SARS-CoV-2. Here, we explored the interaction networks of kinase and COVID-19 crosstalk, and identified phosphoinositide 3-kinase (PI3K)/AKT pathway as the most important kinase signal pathway involving COVID-19. Further, we found a PI3K/AKT signal pathway inhibitor capivasertib restricted the entry of SARS-CoV-2 into cells under non-cytotoxic concentrations. Lastly, the signal axis PI3K/AKT/FYVE finger-containing phosphoinositide kinase (PIKfyve)/PtdIns(3,5)P2 was revealed to play a key role during the cellular entry of viruses including SARS-CoV-2, possibly providing potential antiviral targets. Altogether, our study suggests that the PI3K/AKT kinase inhibitor drugs may be a promising anti-SARS-CoV-2 strategy for clinical application, especially for managing cancer patients with COVID-19 in the pandemic era.
Complete list of metadata

https://hal-amu.archives-ouvertes.fr/hal-03357978
Contributor : Ludovic Leloup Connect in order to contact the contributor
Submitted on : Wednesday, September 29, 2021 - 10:21:22 AM
Last modification on : Tuesday, October 19, 2021 - 10:50:36 PM

Links full text

Identifiers

Collections

Citation

Fang Sun, Chenglin Mu, Hang Fai Kwok, Jiyuan Xu, Yingliang Wu, et al.. Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19. International Journal of Biological Sciences, Ivyspring International Publisher, 2021, 17 (9), pp.2348-2355. ⟨10.7150/ijbs.57810⟩. ⟨hal-03357978⟩

Share

Metrics

Record views

6